Handheld Point of Care Diagnostic

Rapid Handheld Diagnostic for ZIKV, DENV, and CHKV

Organization: Abbott’s Ibis Biosciences Business

Location: Carlsbad, California, USA

Problem: Existing tools to detect ZIKV are laboratory based, require clean facilities, reliable power, and a cold chain that is not readily available in areas of most need. Obtaining early, accurate medical diagnostic information is critical to properly manage the response to ZIKV and other emerging pathogens.

Solution: Ibis proposes to move three technologies from the lab to the field to address critical unmet needs. The team will develop an automated collection, sample preparation and storage cartridge that can be used to purify viral nucleic acids from blood, urine, sputum, and nasal swabs using a Mobile Analysis Platform. They will also enhance an assay for patients presenting with fever to identify viral infection using a finger stick of blood, and a customized assay kit designed for use on the Mobile Analysis Platform. Finally, the team will develop an immunoassay for ZIKV on the Mobile Analysis Platform. They will also enhance an assay for patients presenting with fever to identify viral infection using a finger stick of blood, and a customized assay kit designed for use on the Mobile Analysis Platform. Finally, the team will develop an immunoassay for ZIKV on the Mobile Analysis Platform. The combination of these three technologies will support testing of specimens in the field and provide the ability to extract nucleic acids from blood, urine or swabs using the same hardware that can also be used to perform.

Innovators:

Headshot of Mark Eshoo

Mark Eshoo – PhD in Genetics, University of California at Davis; Genetics/Genomics Post-Doc, Stanford University

"My biggest motivator is the desire to produce diagnostic tools that reduce the suffering and mortality caused by emerging infectious diseases around the world."

Previous Innovations Next